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ABSTRACT

The harmful eﬀects of ZIKA virus (ZIKV) infection are reﬂected by severe neurological manifestations such as microcephaly
in neonates and other complications associated with Guillain-Barré syndrome in adults. The transmission dynamics of
ZIKV in or between neurons, or within the developing brains of the foetuses are not fully understood. Using primary
cultures of murine cortical neurons, we show that ZIKV uses exosomes as mediators of viral transmission between
neurons. Cryo-electron microscopy showed heterogeneous population of neuronal exosomes with a size range of 30–
200 nm. Increased production of exosomes from neuronal cells was noted upon ZIKV infection. Neuronal exosomes
contained both ZIKV viral RNA and protein(s) that were highly infectious to naïve cells. RNaseA and neutralizing
antibodies treatment studies suggest the presence of viral RNA/proteins inside exosomes. Exosomes derived from
time- and dose-dependent incubations showed increasing viral loads suggesting higher packaging and delivery of
ZIKV RNA and proteins. Furthermore, we noted that ZIKV induced both activity and gene expression of neutral
Sphingomyelinase (nSMase)-2/SMPD3, an important molecule that regulates production and release of exosomes.
Silencing of SMPD3 in neurons resulted in reduced viral burden and transmission through exosomes. Treatment with
SMPD3 speciﬁc inhibitor GW4869, signiﬁcantly reduced ZIKV loads in both cortical neurons and in exosomes derived
from these neuronal cells. Taken together, our results suggest that ZIKV modulates SMPD3 activity in cortical neurons
for its infection and transmission through exosomes perhaps leading to severe neuronal death that may result in
neurological manifestations such as microcephaly in the developing embryonic brains.
ARTICLE HISTORY Received 24 April 2018; Revised 21 December 2018; Accepted 27 December 2018
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Introduction
Mosquito-borne Zika virus (ZIKV) is a positive sense
single-stranded RNA virus that belongs to the ﬂavivirus genus of the family Flaviviridae [1]. ZIKV has
been in the spotlight due to its recent epidemic outbreak in Brazil and spread in several parts of the Western Hemisphere including the United States of
America [1–3]. Since more than 60 years, ZIKV existed
in the Zika forest of Uganda and recently has become
an International prominence and Public Health Emergency of International Concern (PHEIC) [1–3]. ZIKV
belongs to the Spondweni serocomplex and is closely
related to dengue (DENV) and West Nile virus
(WNV) [1]. Mostly, infections with ZIKV are asymptomatic (∼80%) with ﬂu-like symptoms and simple
associated clinical manifestations. The sexual transmission of ZIKV, with replicative viral particles being
detectable in semen for at least two months, proposes
it to be a signiﬁcant global threat and a pathogen of
high priority concern to the public health [4,5].

Typically, Aedes aegypti mosquitoes transmit most of
the ZIKV infections to humans. However, ZIKV can
also be transmitted through sexual contacts and transfusions of human blood at the clinical side. In humans,
vertical transmission of ZIKV from mother to neonates
is of the highest concern and has been of focus due to
the associated neurological manifestations [1–3,6–8].
ZIKV infection has been shown to aﬀect both the Central Nervous system (CNS) and the Peripheral Nervous
System (PNS) and is associated with severe neurological complications such as Guillain-Barré syndrome
(GBS with muscle weakness and paralysis) and the
attentive manifestation of microcephaly [1–3,6–12].
Microcephaly, a less studied neurodevelopmental disorder is a marked reduction in brain size and intellectual disability with defective cell proliferation and
severe death of cortical progenitor cells and their neuronal progeny [6,8,11].
Although emergence of ZIKV-associated congenital
microcephaly and neuropathogenesis is being studied
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extensively, this line of research is currently very limited. Since January 2016, signiﬁcant and stunning progress has been made in developing stem cell-based
cellular and animal models [11,13]. In addition to the
identiﬁcation of underlying molecular mechanisms
and development of therapeutics and vaccines, involvement of human tissues and samples has led to the
understanding of ZIKV infections [2,3,7,11,13]. In a
developmental mouse model of ZIKV infection, it has
been shown that astrocytes were targeted throughout
the brain upon entry into the CNS after peripheral
inoculations [3]. ZIKV has been shown to eﬃciently
infect and replicate in mouse neural stem cells
(mNSCs), mouse astroglial cells and diﬀerent regions
of brain including neocortex and hippocampal regions
(CA1 and CA3), thereby raising several concerns
related to long-term memory problems [3,9–12,14].
ZIKV RNA has been detected in neural tissues,
human neural progenitors, matured neurons and has
been correlated with an increase in the apoptosisrelated genes in those neuronal cells [3,9,10,12,14].
The cerebral cortex, a four-layered structure that mediates the higher cognitive functions such as learning
and memory has been severely aﬀected in microcephalic patients [6]. Two independent studies have also
shown that ZIKV infection can drastically reduce the
growth of neural stem cells and brain organoids that
can be directly co-related to the ZIKV-associated congenital microcephaly [8,15,16]. A comparative analysis
approach in the developing neocortex has identiﬁed
ZIKV speciﬁc alterations and preferential infection of
neural stem cells [17]. However, this study does not
address the critical steps of how ZIKV reaches the
brain. Also, the transmission dynamics of ZIKV in
and between neurons or neural stem cells is largely
unknown.
Our recent study showed that Langat virus, a virus
closely related to tick-borne encephalitis virus
(TBEV) uses neuronal exosomes to transmit between
cells [18]. Exosomes are small (30–250 nm) bioactive
functional vesicles derived from the endo-lysosomal
system that exit into the surrounding microenvironments [19–25]. Exosomes are derived from mostly all
of the mammalian cells and they have been shown to
contain cell and cell-state speciﬁc cargo of proteins,
mRNA, and miRNA [26–31]. Recent discoveries of
functional RNA and miRNA in the exosomes has
increased the attention of many researchers that has
led to the emergence of numerous studies in the
identiﬁcation of novel molecules present in the exosomes [28–30,32]. In various pathological conditions
that include tumours, viral infections and tissue
damage, exosomes aid in transmission of cargo from
these sites to other(s) within the human body [32,33].
Exosomes have been shown to play both neuroprotective and toxic roles in the CNS [33]. Several reports
have suggested neuronal exosomes as novel therapeutic

targets for neurological disorders such as Alzheimer’s
disease [33–37]. We have hypothesized that ZIKV
uses exosomes to transmit to other neurons and spread
infection through neuronal connectivity in developing
embryonic foetal and neonatal brains. Our study shows
that mouse cortical neuronal cell-derived exosomes
carry ZIKV infectious RNA and proteins that mediate
viral transmission to other neurons, thereby aiding in
viral dissemination throughout the CNS. Also, our
work suggests that neutral Sphingomyelinase SMPD3
(also referred as nSMase2), an enzyme sphingomyelin
phosphodiesterase is involved in ZIKV infection, replication, and mediates infectious viral RNA and protein
transmission via neuronal exosomes. SMPD3 hydrolyses sphingomyelin to phosphocholine and ceramide
and is predominantly expressed in the neurons of the
CNS to control postnatal growth and development
[38–40]. In addition, SMPD3 has been shown to reside
in Golgi apparatus and is ubiquitously expressed,
thereby suggesting its important role in ZIKV replication [40,41]. Overall, our study not only provides a
model in understanding the importance of exosomes
but can also lead in the progress of new strategies
that include the development of exosomal-based
drugs or therapeutics and/or vaccines to interrupt the
ZIKV infections in neonatal brains.

Results
ZIKV infects mouse cortical neurons in a timeand dose-dependent manner
Smaller head circumference, intellectual ability and seizures that characterizes microcephaly, has been
strongly associated with ZIKA virus (ZIKV) infections
[6,8,11,15–17,42]. Also, a correlation between ZIKV
and reduced neuronal diﬀerentiation or increased cell
death in neuronal cells has been shown [2,3,6,9–
12,14,43]. In order to determine the correct time of
neuronal diﬀerentiation and to address if cells in primary cultures are perhaps not in progenitor state
during ZIKV infection, we plated neuronal cultures
for either 72 or 120 h (post-plating) followed by infection with ZIKV (for another 72 h p.i., 5 MOI; Multiplication of Infection). We infected freshly isolated
primary cultures of murine cortical neurons from
embryonic (E16) developing mouse brains. Primary
cultures were stained for both neuronal marker
MAP-2 (Microtubule Associated Protein-2) or with
GFAP (Glial Fibrillary Acidic protein) an intermediate
ﬁlament protein indicated as astrocyte marker
(Figure 1). At both post plating time points of 72 or
120 h, we found that progenitor cells were fully diﬀerentiated as neurons as revealed by the staining for
MAP-2 (green) followed by detection with Alexa
Fluor 488 (Figure 1). We did not ﬁnd any astrocytes
or other glial cells or neuronal precursor cells (NPCs)
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Figure 1. Murine cortical neurons in primary cultures are diﬀerentiated as neurons from progenitor cells. Phase contrast and ﬂuorescent microscopic images showing primary cultures of cortical neurons from uninfected (UI) or ZIKV (I) infected (MOI 5; 72 h p.i.)
groups at two diﬀerent time points (72 and 120 h post plating). Cortical neurons were stained for neuronal marker (MAP-2) or
astrocyte marker (GFAP) to show the presence of neurons and absence of glial cells. DAPI staining for nuclei serve as internal control. Uninfected neurons serve as control. Representative images obtained from EVOS FL system are shown. Scale bar indicates
200 μm in all panels.

(for GFAP positive staining, and detection with Alexa
Fluor 594) in our primary cultures of murine cortical
neurons at 72 or 120 h of post plating, followed by
infection with ZIKV (for another 72 h) (Figure 1).
Also, the bright ﬁeld (BF) images, predominantly
showed neurons in our primary cultures at both 72
and 120 h post plating of cells (Figure 1). Infection of
primary cultures of cortical neurons at/after 72 or
120 h post plating had no diﬀerences with ZIKV infection. Some of the DAPI-positive but weak MAP-2
stained cells were found to have strong staining for
ZIKV Envelope (E) protein (detected by 4G2 monoclonal antibody, followed by Alexa Fluor 594 secondary
antibody) (Supplementary Fig. 1). We assume that
neurons perhaps have retracted their neurites due to
severe ZIKV infection thereby leading to neuronal
death in those weak MAP-2 stained cells. We also
found that ZIKV readily infected (5 MOI) murine cortical neurons with increased cell death at 96 h post
infection (p.i.) in comparison to the uninfected control
(Figure 2(A)). In addition, cortical neuronal cell death
with ZIKV infection was severe at 120 h p.i., in comparison to infection at early time points, suggesting
longer incubation times lead to severe damage and
neuronal death, perhaps resulting in tissue loss (Figure
2(A)). Several neuronal connections were eliminated
and severe damage was observed due to massive neuronal cell death in murine cortical neurons at 120 h p.i.,

(Figure 2(A)). We did not ﬁnd any morphological
changes or cell loss at earlier tested time points (24,
48 and 72 h p.i.) of ZIKV infection (Figure 2(A)).
The quantitative analysis for assessing cell viability of
primary cultures of cortical neurons by MTT assay
showed reduced number of viable cells at later time
points (72, 96 and 120 h) of ZIKV infection (Figure 2
(B)).
To test that neuronal cell loss, is due to longer incubations with ZIKV infection, we performed an independent experiment with diﬀerent doses (MOI 1, 2.5
and 5) of ZIKV. At 72 h p.i., we did not ﬁnd much considerable morphological changes in cortical neurons
infected with ZIKV at tested doses (of MOI 1, 2.5
and 5) (Supplementary Fig. 2A). However, quantitative
analysis using MTT assay showed some reduction in
cell viability at 72 h post-ZIKV infection with 5 MOI
(Supplementary Fig. 2B). These data suggest that neuronal cell death at 96 h p.i., and onwards is mostly due
to the result of prolonged infection of neurons with
ZIKV and the neuronal stress related to infection.
QRT-PCR analysis performed on the neuronal samples
collected at diﬀerent time points revealed that ZIKV
loads (both E-gene and NS5 mRNA transcripts) were
signiﬁcantly (P < 0.05) high at 72 h p.i., in comparison
to the other tested time points (of 24, 48 and 96 h p.i.,)
(Figure 3(A,B)). The lower loads of ZIKV at 96 h p.i. is
perhaps due to the severe neuronal cell death observed
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Figure 2. Murine cortical neurons in primary cultures are susceptible to ZIKV infection at longer incubation time. (A) Phase contrast
images showing primary cultures of cortical neurons from uninfected (UI) and ZIKV (I) infected (MOI 5) groups at diﬀerent time
points (of 24, 48, 72, 96 and 120 h p.i.). Uninfected neurons serve as control. Representative images obtained from EVOS FL system
are shown. Scale bar indicates 100 μm in all panels. (B) MTT assay showing cell viability of mouse cortical neurons at diﬀerent time
points (of 24, 48, 72, 96, and 120 h p.i.) upon ZIKV infection (5 MOI). Relative optical density shows live cells in culture. Uninfected
controls kept for 120 h were considered as control.

at this time point (Figure 3(A,B)). Immunoblotting
analysis (using highly cross-reactive 4G2 monoclonal
antibody that recognizes the viral Envelope (E)protein) showed similar results with enhanced ZIKV
E-protein at 72 h p.i., in comparison to the loads at
other tested time points (Figure 3(C)). It was also
observed that HSP70 (heat-shock protein 70, an
enriched marker in mammalian exosomes) loads
were enhanced upon ZIKV infection at 48, 72 and
96 h p.i., in comparison to their respective uninfected
controls (Figure 3(C)). HSP70 levels were minimally
detected at 24 h p.i. in the tested conditions (Figure 3
(C)). In addition, a dose-dependent increase in ZIKV
loads was evident both at the RNA (E-gene and NS5
mRNA transcripts) and protein levels when cortical
neurons were infected with 1, 2.5 or 5 MOI at 72 h
p.i. (Figure 3(D–F)). In both time and dose–response
data (Figure 3(A,B,D,E)), NS5 mRNA ampliﬁcation
was found to be higher when compared with the Egene ampliﬁcation, hence we used NS5 detection in
our further analysis. Total protein proﬁle gel images
served as loading controls in the immunoblotting
analysis (Figure 3(C,F)). Densitometry analysis from

total cell lysates showed the quantitative diﬀerences
in E-protein (from both the time point and dose–
response) and HSP70 levels observed between the
ZIKV infected (MOI 5) and uninfected controls (Supplementary Fig. 3A–C). Collectively, these data suggest
time- and dose-dependent infection kinetics of ZIKV
in mouse cortical neurons.
Cortical neuronal cell-derived exosomes contain
ZIKV RNA and protein
Regardless of the importance of ZIKV infection and its
cause of severe neurological complications such as GBS
and the more attentive manifestation of microcephaly
in neonates, we know little about the transmission
modes of ZIKV within the neonatal and adult brain
cells. Increased HSP70 levels in neuronal cells upon
infection (Figure 3(C)) suggest that ZIKV perhaps
uses neuronal exosomes for transmission and spread
of infection in the brain. It has been shown that cortical
neurons release exosomes in culture that contain
enriched exosomal markers [18,44]. Due to increased
viral loads at 72 h p.i., we considered this time point
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Figure 3. ZIKV infects primary cultures of cortical neurons in a time- and dose-dependent manner. QRT-PCR analysis showing ZIKV
loads (MOI 5) determined by either E-gene (A) or NS5 (B) mRNA transcripts in neuronal cells at diﬀerent time points (of 24, 48, 72
and 96 h p.i.). Uninfected cells (UI) at indicated time points served as controls. (C) Immunoblotting analysis showing ZIKV E-protein
levels at diﬀerent time points (24, 48, 72 and 96 h p.i. and at 5MOI). HSP70 loads serve as internal control. ZIKV loads at diﬀerent
MOI of infection (1, 2.5, 5 MOI) determined by either E-gene (D) or NS5 (E) mRNA transcripts is shown from 72 h p.i. (F) Immunoblot
showing viral E-protein loads in cortical neurons upon infection with various doses (1, 2.5, 5 MOI). Uninfected cells were used as
control in all panels. Total protein proﬁles shown by Coomassie-stained gels (in C and F) serve as loading controls. ZIKV loads for Egene or NS5 mRNA transcripts are shown in both (A, D) or (B, E). E-gene or NS5 transcript levels were normalized to mouse betaactin in (A, D) or (B, E). P value determined by Student’s two-tail t-test is shown.

for the isolation of exosomes from cortical neuronal
cultures. Using either density gradient centrifugation
technique; OptiPrep™ (DG-Exo isolation), or by
diﬀerential ultracentrifugation, we isolated exosomes
from murine cortical neurons [18,45,46]. Detailed protocols and descriptions are published in our recent
work on neuronal exosomes [18]. Cryo-Electron
Microscopy (EM) performed on neuronal cell-derived
exosomes showed their sizes in the ranges of 30–
200 nm in diameter (Figure 4(A)) that are similar to
exosomes isolated from other mammalian cells. Quantitative analysis of the heterogeneous populations of
neuronal exosomes was performed to determine any
diﬀerences between ZIKV-infected and uninfected
cell-derived exosomes (Figure 4(B,C)). We found that
highest percentage of exosomes were of sizes between
50–100 nm and 100–150 nm (in diameter) in both
uninfected and ZIKV-infected groups (Figure 4(B,
C)). However, ZIKV infected neuronal cell-derived
exosomes had increased percentages in 0–50 nm but
decreased percentages in 100–150 nm and 150–
200 nm sizes in comparison to the uninfected group
(Figure 4(B,C)). Also, higher percentages of larger exosomes or Extracellular Vesicles (EVs) of sizes 200–
500 nm were observed upon ZIKV infection in comparison to the uninfected group (Figure 4(B,C)). In
addition, we noted higher number of exosomes in
cryo-EM images collected from ZIKV-infected (n =
25) group in comparison to the uninfected (n = 13)

group (Figure 4(D)). These data suggest increased production and or release of neuronal exosomes upon
ZIKV infection.
To ﬁnd whether ZIKV proteins are evident in neuronal exosomes, we collected six diﬀerent fractions
from samples collected at 72 h p.i., following the OptiPrep™ (DG-Exo) isolation method as described in
[18,45]. Neuronal HSP70 was detected in 20 µl of
the infected exosomes from three to ﬁve fractions.
Barely detectable levels of HSP70 were noted in fractions one, two and six but enhanced levels were
noted in fractions three to ﬁve (Figure 4(E)). HSP70
loads were also detected in exosomal fractions threeﬁve obtained from uninfected cortical neuronal cells,
but with higher levels in fractions ﬁve (Figure 4(E)).
Additionally, for detailed characterization of exosomes, we detected the presence of other exosomal
markers such as CD63 and CD9 in fractions from
both ZIKV-infected and uninfected groups (Figure 4
(E)). CD63 loads were enriched in fractions three-six
in ZIKV infected and fractions four-six in uninfected
controls. Barely detectable loads were observed in one
and two fractions in both infected and uninfected
groups (Figure 4(E)). CD9 was also enriched in fractions four and ﬁve in both ZIKV-infected and uninfected controls, and detectable levels were found in
fractions two and three of the infected group (Figure 4
(E)). In other fractions one and six, we could not
detect CD9 loads (Figure 4(E)). We also found that
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Figure 4. Exosomes derived from murine cortical neuronal cells are in heterogenous populations and contain infectious ZIKV RNA
and E-protein. (A) Cryo-EM representative images showing exosomes isolated from uninfected (UI) or ZIKV-infected (I) (MOI 5; 72 h
p.i.), cortical neuronal cells. Scale bar indicates 100 nm. Size distribution of exosomes isolated from uninfected (B) or ZIKV-infected
(C) neuronal cells are shown. The Y-axis represents exosome number and X-axis indicate exosome size in diameter (e.g. 0–50 nm). N
indicates total number of exosomes counted from diﬀerent cryo-EM images. Percentages were calculated based on the total number of exosomes in each size range. (D) Exosome numbers counted from uninfected and ZIKV-infected groups is shown. The Y-axis
represents exosome number and X-axis indicates samples analysed. N indicates total number of images used in this counting analysis. P value determined by Student’s two-tail t-test is shown. (E) Immunoblotting images from OptiPrep density gradient exosomes
preparation (DG-Exo-isolation) showing enhanced ZIKV-E (MOI 5, 72 h p.i.) protein loads and presence of HSP70, CD63 and CD9
(exosomal markers) in diﬀerent exosome fractions. Exosomes derived from uninfected cells served as control. Roman numerical
indicates the fraction numbers (I being the top and VI being the small fraction at the bottom of the iodixanol density gradient).
(F) Infection (72 h p.i.) of naïve primary cultures of murine cortical neurons showing increased infectivity and transmission from
infectious exosomal fractions four, ﬁve and six in comparison to other lower fractions (1–3). (G) QRT-PCR showing ZIKV (I) RNA
loads (MOI 5) from cortical neuronal cell-derived exosomes at diﬀerent time points (24, 48, 72 and 96 h p.i.). Uninfected (UI)
group from each respective time point serve as controls. (H) Immunoblotting showing the ZIKV-E protein loads (MOI 5) and
HSP70 levels in neuronal cell-derived exosomes isolated at diﬀerent time point samples (24, 48, 72, and 96 h p.i.). HSP70 loads
show the presence and enrichment of exosomal marker and serve as internal control. (I) ZIKV loads from neuronal cell-derived exosomes collected from cortical neurons infected with diﬀerent doses (MOI 1, 2.5 and 5) at 72 h p.i., is shown. (J) Immunoblotting
showing ZIKV-E protein loads at diﬀerent doses (MOI 1, 2.5 and 5, at 72 h p.i.) of infection (I) in neuronal cell-derived exosomes
collected from infected-cortical neurons. Uninfected (UI) cell-derived exosomes collected from uninfected cortical neurons serve
as control in (I) and (J). Total protein proﬁles serve as control in (H) and (J). In both (G) and (I), ZIKV NS5 transcripts were normalized
to mouse beta-actin transcripts. P value determined by Student’s two-tail t-test is shown.

ZIKV E-protein levels were enhanced in infected exosomal fraction four, however, other fractions (two,
three and ﬁve) also showed weak signal for E-protein
(Figure 4(E)). As expected, ZIKV E-protein was not
detected in any uninfected fractions (Figure 4(E)).
Since most of the ZIKV-E protein was detected in
fraction four (the fraction with enhanced levels of all
tested exosomal markers), we assessed this fraction
for the presence of more viral RNA/proteins and
their correspondence to increased infectivity on the
naïve recipient cells. We found that naïve primary cultures of murine cortical neurons infected via incubations (for 72 h) with infectious exosomes from
diﬀerent fractions (collected from ZIKV-infected

cortical neurons, at 72 h p.i., and 5 MOI) showed
highest infectivity with fraction four (Figure 4(F)).
Exosomes from lower fractions ﬁve, and six also
showed increased infectivity when compared with
the upper (1–3) fractions (Figure 4(F)). Next, we
tested the loads of ZIKV in exosomes collected from
cortical neurons infected at diﬀerent time points (of
24, 48, 72 and 96 h p.i., 5 MOI). Similar to viral
loads observed in cortical neuronal cells, ZIKV RNA
loads were signiﬁcantly (P < 0.05) higher at 72 h p.i.,
in comparison to the other tested time points (of 24,
48 and 96 h p.i.) (Figure 4(G)). The lower loads of
ZIKV at 96 h p.i., is perhaps due to the neuronal
cell death observed at this time point (Figure 2(A)).
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We assume that less number of exosomes were
released due to massive death of neurons at 96 h
p.i., (Figure 4(G)). Immunoblotting with 4G2 antibody showed increased ZIKV E-protein loads at
72 h p.i., in a time-dependent manner in comparison
to the viral loads at 24 and 48 h p.i., (Figure 4(H)).
The reduced loads of ZIKV RNA and E-protein at
96 h p.i., corresponds to the severe neuronal loss at
this time point (Figure 4(G,H)). Detection of HSP70
in neuronal cell-derived exosomes further supported
the presence of exosomal marker in both uninfected
and infected exosomal lysates (Figure 4(H)). Furthermore, increased ZIKV RNA and E-protein loads were
noted in neuronal exosomes with an increase in viral
doses from 1, 2.5 and 5 MOI at 72 h p.i., (Figure 4(I,
J)). Total protein proﬁles served as loading controls in
the immunoblotting analysis (Figure 4(H,J)). Densitometry analysis from total exosomal lysates showed the
quantitative diﬀerences in E protein (from both the
time point and dose–response analysis) and HSP70
levels (time points) observed between the ZIKV
infected (MOI 5) and uninfected controls (Supplementary Fig. 3D–F). These data suggest that cortical neuronal cell-derived exosomes contained ZIKV
RNA and E-protein with enhanced loads.
ZIKV RNA and proteins are infectious and are
securely contained inside the exosomes for
transmission
We performed RNaseA-treatment assays, to test the
possibility that ZIKV RNA is not perhaps outside the
exosomes (in PBS suspensions) and hence taken up
by the recipient cells. Neuronal exosomes derived
from ZIKV-infected cells (from 72 h p.i., 5 MOI)
were freshly isolated (resuspended in PBS) and treated
with RNase A (5 μg/ml, for 15 min, at 37°C). We did
not ﬁnd any diﬀerences in ZIKV NS5 transcript loads
from infected-treated or untreated groups (Figure 5
(A)). The uninfected group treated with RNaseA
served as an internal control (Figure 5(A)). The laboratory generated viral stocks (5 MOI) with known titres
(collected from 14 days p.i., Vero cell culture supernatants) were treated with RNaseA, in order to not
exclude the eﬀect of RNaseA on viruses. No diﬀerences
were noted in viral loads determined from naïve cortical neuronal cells upon incubation with laboratory viral
stocks prepared from RNaseA-treated or untreated
groups (Figure 5(A)). Similar to our previous results
with DENV2 [47], we assume that the ﬂavivirus RNA
genome is inside exosomes/virions and is not available
for RNaseA-mediated degradation. Next, we tested
whether exosome-mediated viral transmission is
dependent on ZIKV E-protein in naïve cortical neuronal cells. We treated infectious exosomes (containing
viral RNA and proteins inside exosomes) or laboratory
prepared viral stocks (high infectious dose of MOI 8 or
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low dose of MOI 0.8) with antibodies (3 µg of each)
ZV-2, ZV-16 or with highly potent neutralizing antibodies ZV-54, ZV-67 [48] for 4 h at 37°C followed by
infection (for 72 h) of naïve mouse cortical neuronal
cells. No diﬀerences in ZIKV loads were noted in neuronal cells incubated with infectious exosomes that were
treated with either ZV-2 or ZV-16 or with ZV-54 or
ZV-67 neutralizing antibodies in comparison to their
respective untreated controls (Figure 5(B)). Antibody
treatments of exosomes from uninfected cells were
used as internal controls for the infectious exosome
group (Figure 5(B)). We found a signiﬁcant reduction
in ZIKV loads in neuronal cells incubated with ZV-2,
ZV-16 or ZV-54, ZV-67 antibodies treated with high
(8 MOI) or low (0.8 MOI) doses of laboratory viral
stocks when compared with their respective untreated
controls (Figure 5(B)). Also, ZV-54 and ZV-67 antibodies treatments with high (8 MOI) or low (0.8
MOI) doses of laboratory viral stocks showed signiﬁcantly (P < 0.05) higher neutralization eﬀects when
compared with ZV-2 or ZV-16 antibodies, in both
the high and low viral doses groups (Figure 5(B)).
Additionally, we performed immunoﬂuorescence
assays (IFA) on neuronal cells (using 4G2 monoclonal
antibody for detection). Similar results were obtained
from infectivity assays showing no diﬀerences in
ZIKV E-protein staining of neuronal cells that were
incubated with infectious exosomes that were either
kept untreated or treated with ZV-2, ZV-16 or highly
potent ZV-54 or ZV-67 neutralizing antibodies (Supplementary Fig. 4). In case of neuronal cells incubated
with high (8 MOI) or low (0.8 MOI) viral doses of
ZIKV (pre-treated with either ZV-2, ZV-16 or ZV54, ZV-67 antibodies), neutralization eﬀects corresponding to lower detection of viral E-protein/staining
and less ﬂuorescently labelled cells was evident in comparison to their respective untreated controls (Supplementary Figs. 5 and 6). It was also noted that in
comparison to ZV-2 and ZV-16, the highly potent
ZV-54 or ZV-67 antibodies had stronger neutralization
eﬀects with dramatically reduced E-protein stained
positive cells. Next, we treated cortical neurons with
5 µg of 4G2 antibody (that poorly neutralizes ZIKV),
followed by infection via exosomes isolated from
ZIKV-infected (72 h p.i., 5 MOI) neuronal cells, to analyse if treatment with 4G2 antibody aﬀects or blocks
viral transmission (Figure 5(C)). No diﬀerences in
viral loads were found in antibody-treated or untreated
groups of neuronal cells upon incubation of infectious
exosomes isolated from ZIKV-infected neurons (Figure
5(C)). Addition of ZIKV laboratory stocks with known
titres (MOI 5) showed reduced viral loads in cortical neuronal cells treated with 4G2 antibody in comparison to the
untreated controls (Figure 5(C)). These results suggest
that E-protein is securely contained inside the exosomes.
However, E-protein on the surface of the virions is accessible to ZV-2, ZV-16, ZV-54 or ZV-67 or 4G2 antibodies
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Figure 5. Exosomes from primary cultures of cortical neurons are infectious and transmit ZIKV to naïve neuronal cells. (A) Infections
via freshly prepared exosomes from ZIKV-infected (MOI 5, 72 h p.i.) cortical neuronal cells or laboratory ZIKV viral stocks treated with
RNaseA on naïve cortical neuronal cells (72 h p.i.) are shown. Untreated ZIKV-infected or RNaseA-treated uninfected exosome or
untreated-virus stock groups serve as controls. (B) ZIKV loads (72 h p.i.) in neuronal cells incubated with ZIKV-infectious exosomes
or laboratory viral stocks (8 MOI as high dose or 0.8 MOI as low dose) treated with ZV-2, ZV-16 or ZV-54, ZV-67 antibodies is shown.
Cells incubated with uninfected cell-derived exosomes serves as control for infectious exosome group. The untreated (no antibody
treatment) groups included in all panels, respectively serves as controls. C) QRT-PCR analysis showing viral loads in cortical neurons
treated with 4G2 antibody followed by infection with exosomes (collected from independent batch of ZIKV-infected (MOI 5; 72 h
p.i.) cortical neurons) or laboratory viral stocks. Untreated groups (–) serve as controls. ns indicates no signiﬁcance in exosome or
virus-treated groups. (D) Representative ﬂuorescent images showing detection of E-protein in neuronal cells infected via exosomes
(upper panel) derived from independent batch of ZIKV-infected (MOI 5; 72 h p.i.) cortical neurons or infected using ZIKV laboratory
viral stocks (for 72 h p.i., lower panel). Neuronal cells treated with exosome-depleted supernatant (sup, in a similar ratio) served as
control for exosome group. Uninfected cells serve as control for ZIKV laboratory stock infected group. Scale bar indicates 200 µm in
all panels. (E) Quantitative assessment of number of ZIKV-infected (positive for ﬂuorescence, detected by 4G2 antibody) (MOI 5; 72 h
p.i.) neuronal cells treated with exosomes (in dilution 6) or supernatant fractions is shown. (F) Quantitative assessment of number of
ﬂuorescent neuronal cells, (detected by 4G2 antibody) infected (MOI 5; 72 h p.i.) with laboratory ZIKV viral stocks is shown. G) ZIKV
loads in cortical neuronal cells (at diﬀerent time points of 24, 48, 72 and 96 h p.i., and 5 MOI) infected via infectious exosomes is
shown in naïve cortical neuronal cells for transmission and replication of viral RNA. In panels A, B, and F, ZIKV loads are indicated
based on NS5 transcripts normalized to mouse beta-actin transcript levels. P value determined by Student’s two-tail t-test is shown.

and treatment with these antibodies showed diﬀerential neutralizing eﬀects upon use of laboratory viral
stocks. These data further suggest that E-protein is perhaps not on the surface of exosomes and may not be
required for mediating viral RNA and protein transmission via exosomes. To determine, if exosomesmediated viral transmission is clathrin-dependent, we
treated cortical neuronal cells with clathrin speciﬁc
inhibitor (Pitstop-2; 30 µM for 15 min), and infected

these Pitstop-2 treated cells with infectious exosomes
derived from ZIKV-infected (5 MOI; 72 h p.i.) cortical
neuronal cells. We did not ﬁnd any diﬀerences in ZIKV
loads (at 72 h p.i. of naïve cortical neuronal cells) in
Pitstop-2 treated group in comparison to the DMSO
(vehicle)-treated controls (Supplementary Fig. 7).
These results suggest that exosome-mediated ZIKV
transmission to naïve neuronal cells is clathrin
independent.
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To test whether exosomal RNA was infectious to naïve
cortical neuronal cells, we determined the viral titres in
exosomes by performing a virus dilution assay. Representative images from neuronal cells infected via incubations
with exosomes or exosome-depleted supernatants (collected during the exosome isolation methods) are
shown from the virus dilution assay (Figure 5(D)).
Increased ﬂuorescent signal (as determined by immunostaining with 4G2 antibody) was evident in neurons
infected with infectious exosomes in comparison to infection via supernatant fraction (Figure 5(D)). As an internal
control, we also performed the viral dilution assay on cortical neuronal cells by infecting with ZIKV laboratory
virus stocks (5 MOI, 72 h p.i.). Exosome-mediated
ZIKV-infected cells detected enhanced E-protein staining
with 4G2 antibody in comparison to the supernatantfraction-treated cells (Figure 5(D)). Phase contrast images
(from both groups either treated with exosomes or laboratory viral stocks) showed similar morphology of
infected-neuronal cells (Figure 5(D)). Quantiﬁcation of
ﬂuorescent signals (determined by counting the percentages of ﬂuorescently labelled infected cells staining the
E-protein) in neuronal cells infected with exosome fraction in comparison to the supernatant fraction (for 72 h
p.i.) further supported the microscopic observation
(Figure 5(E)). Dilution six was considered for both microscopic and quantitative analysis of infected cells from
each replicate. The quantiﬁcation of ﬂuorescent signals
(determined by counting the percentages of ﬂuorescently
labelled infected cells showing the E-protein staining by
4G2 monoclonal antibody) in neuronal cells infected
with laboratory virus stocks of ZIKV (5 MOI, 72 h p.i.)
showed infectivity of the viral stocks (Figure 5(F)).
Next, we tested whether exosomes isolated from ZIKVinfected neuronal cells (from 72 h p.i., 5 MOI) are infectious and replicative in uninfected/naïve cells. QRT-PCR
analysis showed that murine cortical neuronal cells treated with ZIKV-infected neuronal-cell-derived exosomes
(isolated from an independent batch of infected cells)
readily transmitted infectious exosomal RNA to uninfected recipient neuronal cells (Figure 5(G)). Also, we
noted that infectious exosomal RNA replicated in the
naïve/uninfected neuronal cells in a time-dependent
manner at the tested time points of 24, 48, 72 and 96 h
p.i. (Figure 5(G)). These data suggest that neuronal exosomal RNA is infectious, viable, and replicative in naïve
recipient cortical neuronal cells of the CNS.
Neutral Sphingomyelinase SMPD3 (nSMase2)
facilitates ZIKV infection and transmission via
exosomes
It has been shown that the membrane-associated enzyme
SMPD3 (nSMase2; 71 kDa) is one of the most studied
neutral Sphingomyelinase that is activated by anionic
phospholipids such as phosphatidylserine (PS) and phosphatidic acid (PA) [38–41]. Activation of SMPD3 in cells
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plays an important role in the cellular responses [38–41].
We tested the activation of nSMase upon ZIKV infection
in both neuronal cells and exosomes re-suspended in
PBS. At both tested time points (24 and 72 h p.i.), neutral
Sphingomyelinase activity (measured as milliunits) was
signiﬁcantly (P < 0.05) enhanced in ZIKV-infected cortical neurons and in exosomes derived from these neuronal cells (Figure 6(A,B)). In order to address if the
increase in Sphingomyelinase activity is dependent on
the cell number and production/release of exosomes,
we plated murine cortical neurons at diﬀerent cell densities and collected cells and exosomes at 72 h p.i.,
from ZIKV infected (5 MOI) or uninfected controls.
Not many diﬀerences were found in Sphingomyelinase
activity from cells plated at diﬀerent densities, perhaps
the growing cells had maintained the same fold of
SMPD3 activity (Figure 6(C)). We found an increase in
Sphingomyelinase activity in exosomes derived from
varying number of cells plated in increasing densities
and this also reﬂected an increase in exosome release
from ZIKV infected cells (Figure 6(D)). This data also
correlate with the increasing amounts of total proteins
extracted from either cells or exosomes collected from
ZIKV-infected (5 MOI) or uninfected controls (Supplementary Fig. 8A–F). No signiﬁcant (P < 0.05) diﬀerences were noted in total protein amounts collected
from ZIKV-infected or uninfected cells and neither from
total proteins estimated from ZIKV-infected or uninfected
exosomal lysates (Supplementary Fig. 8(B,C, E,F)). We
also found that ZIKV infection, signiﬁcantly (P < 0.05)
upregulated smpd3 transcripts levels in neuronal cells
at both 72 and 96 h p.i. (Figure 6(E)). No diﬀerences
in smpd3 transcript levels were noted in exosomal fractions collected from ZIKV-infected group, when compared with the uninfected controls (Figure 6(F)). Since
exosomal smpd3 transcripts were normalized to actin
(Figure 6(F)), we double conﬁrmed that this is not due
to lower actin transcripts in exosomes. QRT-PCR analysis for GAPDH loads and normalization to the smpd3
transcripts with either of the housekeeping genes showed
no signiﬁcant (P < 0.05) diﬀerences (Supplementary Fig.
8G). Similar to the smpd3 transcripts levels, the SMPD3
protein loads were upregulated at both 72 and 96 h p.i.,
in ZIKV-infected neuronal cell lysates in comparison
to the uninfected controls (Figure 6(G)). Total protein
proﬁle gel image served as loading control (Figure 6
(G)). Densitometry analysis from total cell lysates
showed the quantitative diﬀerences in SMPD3 protein
levels (from diﬀerent time points) observed between
the ZIKV infected (MOI 5) and uninfected controls
(Supplementary Fig. 8H). Silencing of smpd3 by siRNA
treatment showed signiﬁcantly (P < 0.05) lower loads of
smpd3 transcript levels at 72 h ZIKV p.i., in comparison
to the untreated or scrambled siRNA-treated control
groups (Figure 6(H)). Signiﬁcantly (P < 0.05) reduced
ZIKV loads were noted in smpd3-siRNA- treated cells
in comparison to untreated or scrambled-siRNA-treated
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Figure 6. ZIKV induces expression of SMPD3, a neutral sphingomyelinase critical for exosome production and release. Neutral
sphingomyelinase activity assays performed on cell lysates (A) or exosomal lysates (B) are shown. Neuronal cell and exosomal lysates
derived from ZIKV-infected (MOI 5) was used from 24 and 72 h p.i. Lysates from uninfected neurons or exosomes served as controls.
The Y-axis represents activity of neutral sphingomyelinases (shown in milliunits) and X-axis indicates the hours in each panel.
SMPD3 activity (measured over the amount of total proteins) in neuronal cells (C) or in neuronal cell-derived exosomes (D) determined from diﬀerent number/densities of plated cells is shown. White bar indicates uninfected and black bar denotes infected
groups. Asterisk indicates signiﬁcance. (E) QRT-PCR analysis showing expression of smpd3 mRNA transcripts in uninfected (UI) or
ZIKV-infected (I) (MOI 5) cortical neuronal cells or in cortical neuronal cell-derived exosomes (F) isolated at diﬀerent time points
(24, 48 72 and 96 h p.i.). (G) Immunoblotting analysis showing SMPD3 protein levels in uninfected (UI) or ZIKV-infected (I) cortical
neuronal cells at 24, 48 72 and 96 h p.i.. Total protein proﬁle image from coomassie-stained gel served as control. QRT-PCR analysis
showing expression of smpd3 (H) or ZIKV NS5 mRNA transcript loads (I), to reveal silencing eﬃciency (H) or viral burden (I) in
untreated (UT) or smpd3 speciﬁc siRNA or scrambled siRNA-treated ZIKV-infected (MOI 5; 72 h p.i.) murine cortical neuronal
cells. Untreated cells were used as controls. The smpd3 or ZIKV NS5 gene transcript levels were normalized to mouse beta-actin
levels. P value determined by Student’s two-tail t-test is shown.

control groups (Figure 6(I)). These data suggest that
SMPD3 facilitates ZIKV infection in murine cortical
neurons.
Exosome-release inhibitor GW4869 reduced
ZIKV loads and transmission through SMPD3
It has been reported that inhibition of nSMases with
inhibitor GW4869 or by silencing through siRNA
alters the metabolite composition of cells and extracellular vesicles (EVs) thereby, blocking the release of
exosomes [18,39,49]. We tested the eﬀects of
GW4869 inhibitor on exosome budding and release
upon ZIKV infection in murine cortical neurons.
GW4869 inhibitor treatment (20 µM) showed signiﬁcantly (P < 0.05) reduced loads of ZIKV in cortical
neuronal cells infected (5 MOI, and at diﬀerent time
points of 24, 48 and 72 h p.i.) (Figure 7A–C). No diﬀerences in ZIKV loads were noted when neuronal cells
were treated with lower doses (5 and 10 µM) of

GW4869 inhibitor. Also, it was noted that the
reduction in ZIKV loads in murine cortical neurons
was dose- and time-dependent, where at 72 h p.i.
GW4869 treatments at 20 µM concentrations showed
a dramatic reduction in viral loads when compared
with the mock (vehicle; DMSO) treated groups
(Figure 7A–C). Immunoblotting with 4G2 antibody
showed reduced ZIKV E-protein loads upon
GW4869 treatment at 20-µM concentrations in comparison to the other tested doses of 5 and 10 µM and
respective time points (24, 48 and 72 h p.i.,) and
DMSO controls (Figure 7(D)). At 72 h p.i., treatment
with GW4869 at 20 µM concentration, showed greater
reduction in ZIKV E-protein loads in comparison to
the early tested time points of 24 and 48 h p.i., (Figure 7
(D)). Total protein proﬁle gel images from respective
time points (24, 48 and 72 h p.i.) of ZIKV-infected
neuronal cells served as loading control (Figure 7
(D)). In addition to the murine cortical neuronal
cells, we analysed the potential eﬀects of GW4869
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Figure 7. Treatment with exosome inhibitor aﬀects ZIKV burden in murine cortical neuronal cells. QRT-PCR analysis showing
expression of NS5 mRNA transcripts to reveal viral burden in cortical neuronal cells infected with ZIKV (MOI 5) at diﬀerent time
points of 24 (A), 48 (B) and 72 (C) h p.i. ZIKV NS5 gene transcript levels were normalized to mouse beta-actin levels. P value determined by Student’s two-tail t-test is shown. (D) Immunoblotting analysis showing levels of viral E-protein in ZIKV-infected (MOI 5)
cortical neuronal cell lysates from diﬀerent time points (24, 48 and 72 h p.i.) of infection. GW4869 inhibitor was treated for four
hours at tested doses of 5, 10 or 20 µM and at indicated time points of 24, 48 and 72 h p.i.. Lysates prepared from DMSO-treated
cells serves as mock control. Total protein proﬁle images from coomassie-stained gels served as control in (D).

inhibitor on exosome release from ZIKV-infected cortical neurons. QRT-PCR analysis showed that exosomes derived from cortical neuronal cells treated
with GW4869 inhibitor (at all tested doses of 5, 10
and 20 µM; and time points of 24, 48 and 72 h p.i.)
had signiﬁcantly (P < 0.05) reduced loads of ZIKV
RNA in comparison to the DMSO control (Figure 8
(A–C)). This reduction in ZIKV loads was more evident in exosomes, when compared with the reduction
observed in cortical neuronal cells that released these
exosomes (Figure 7(A–C) and Figure 8(A–C)). Similar
to reduced ZIKV RNA, we found that ZIKV E-protein
loads were also considerably reduced in cortical neuronal cell-derived exosomes at all the tested doses (5,
10, and 20 µM) and time points (24, 48 and 72 h p.i.)
in comparison to their respective DMSO controls
(Figure 8(D)). Total protein proﬁle gel images from
diﬀerent time points (24, 48 and 72 h p.i.) of ZIKVinfected neuronal cell-derived exosomes served as loading control (Figure 8(D)). Densitometry analysis from
total cell (for data shown in Figure 7(D)) and exosomal
(for data shown in Figure 8(D)) lysates revealed the
quantitative diﬀerences in E protein loads (from the
GW4869 time points and dose–response immunoblot
analysis) observed between the ZIKV infected (MOI 5)
and uninfected controls (Supplementary Fig. 9A–C;

for immunoblots shown in Fig. 7D and Supplementary
Fig. 9D–F; for immunoblots shown in Fig. 8D). Furthermore, we found that upon treatment with GW4869
inhibitor, smpd3 transcript levels in both cortical neurons (Supplementary Fig. 10A–C) and neuronal exosomes (Supplementary Fig. 10D–F) were signiﬁcantly
(P < 0.05) reduced (at 20 µM dose in cortical neurons
and all tested doses of 5, 10 and 20 µM in neuronal
exosomes at time points of 24, 48 and 72 h p.i.) in comparison to their respective DMSO-treated controls (Supplementary Fig. 11). Similar to ZIKV loads, smpd3
transcript levels were also lower in exosomes when compared with the infected-cortical neuronal cells (Supplementary Fig. 10). These data suggest that exosome
release inhibitor GW4869, blocks SMPD3-mediated
ZIKV transmission and infection in cortical neurons.

Discussion
Neurotransmission also called synaptic transmission is
a process by which neurons communicate with oneanother and send electrical impulses and signalling
molecules/chemicals including neurotransmitters
[50]. Axonal terminals of the sending (presynaptic)
neuron releases the neurotransmitters including other
cargo that binds to and activates the receptors or
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Figure 8. Treatment with GW4869 aﬀects ZIKV burden in murine cortical neuronal cell-derived exosomes. QRT-PCR analysis showing expression of NS5 transcripts to reveal viral burden in ZIKV-infected (MOI 5) cortical neuronal cell-derived exosomes collected at
diﬀerent time points of 24 (A), 48 (B) and 72 (C) h p.i.. ZIKV NS5 gene transcript levels were normalized to mouse beta-actin levels. P
value determined by Student’s two-tail t-test is shown. (D) Immunoblotting analysis showing levels of viral E-protein in ZIKVinfected (MOI 5) cortical neuronal cell-derived exosomal lysates at diﬀerent time points (24, 48, and 72 h p.i.) of infection.
GW4869 inhibitor was tested at 5, 10, or 20 µM concentrations and at indicated time points. Lysates prepared from DMSO-treated
cells serves as mock control. Total protein proﬁle images from coomassie-stained gels served as control in (D).

channels on the dendrites of a receiving (postsynaptic)
neuron. With this tightly regulated process of neurotransmission from sending neurons to the receiving
neuron, the discharge of exosomes from sending neuronal cells and entry of exosomes into neighbouring
receiving neuronal cells takes place on a continuous
basis. Within a neural presynaptic terminal, two
kinds of small membrane nanovesicles such as synaptic
vesicles (SVs; that are ∼35–55 nm in diameter) and
exosomes (inside Multivesicular Bodies (MVBs); that
are 50–200 nm in diameter) are discharged [33,44].
Exosomes have been shown to represent a variety of
intercellular exchange of eﬀector molecules in order
to allow presynaptic neurons to modify gene and
protein expression in postsynaptic neurons [33,44].
Neuronal exosomes have shown to transfer both membrane and cytoplasmic proteins, functional lipids
(involved in signal transduction) or RNA [33,44]. In
receiving neuronal cells, exosomal mRNA will be translated and the small RNA, including the miRNA that
mediates gene silencing is activated to bind speciﬁc
genes for suppression [33,44]. Recent discoveries of
functional RNA, miRNA and proteins in the exosomes
has increased the attention that has led to the emergence of numerous studies in identifying novel molecules present in neuronal exosomes [18,19,29–32].
Due to the occurrence of RNA in the exosomes, we

hypothesized whether exosomes are also carriers of
viral RNA from the latest emerging ZIKV. Exosomes
have been shown as vehicles of transmission for a variety of microorganisms, and our recent ﬁndings of Langat virus (LGTV; a member close to the tick-borne
encephalitis virus; TBEV) and WNV transmission
through neuronal exosomes has provided new insights
into vector-borne ﬂaviviral diseases drug discovery
[18,32,51–57]. Our recent study has also shown that
dengue virus (Serotype 2; DENV2) entire viral RNA
genome is present and transmitted via mosquito cellderived exosomes [47]. In this study, we have shown
that ZIKV RNA and proteins are securely transported
to the neuronal cells through infectious exosomes. So
far, no studies have elucidated whether ZIKV-caused
neurological manifestations such as microcephaly
involves host neuronal exosomes.
Our discovery that neuronal cell-derived exosomes
are the carriers of mosquito-borne ﬂavivirus infectious
RNA and proteins suggest a novel mode of ZIKV transmission. In our studies with ZIKV infections, the presence of MAP-2 (neuronal marker) and absence of
GFAP (astrocyte glial marker) clearly indicated the
complete neuronal diﬀerentiation of progenitor cells
to cortical neurons in our studies with ZIKV infections.
The data with weak or absence of MAP-2 staining, and
positive DAPI staining showing enhanced ZIKV E-
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protein levels, suggested that perhaps there is neurite
retraction due to induction of cell death in ZIKVinfected neurons. Increased neuronal death at 120 h
p.i., in comparison to the 72 h p.i., of murine cortical
neurons infected with ZIKV (MOI 5) suggests that
longer incubation hours and increasing infectious
dose could be responsible for the massive death of cortical neurons and their connections in developing
brains. Also increased viral loads at 72 h p.i., (at both
mRNA and protein levels) in neuronal cells and neuronal cell-derived exosomes, suggest a timing of peak
induction in viral replication in neurons and their
transmission through exosomes. The observation of
high ZIKV loads in neurons suggests that viral RNA
and proteins could be simply transferred in exosomes
via axonal transportation. Early diagnosis and detection of ZIKV infections in mothers could possibly
allow strategies to block the transport and/or dissemination of viral RNA and proteins that cause damage to
the neonatal cells. We assume that cortical neurons are
severely damaged leading to death and loss in networking that perhaps results in small brain size in microcephalic brains. It has been shown that endoplasmic
reticulum stress in embryonic brains (in vivo) results
in unfolded protein response during ZIKV infection
and associated microcephalic condition [58]. Inductions in HSP70 loads during ZIKV-infection or in
uninfected cells over the period of post incubations of
cortical neuronal cells suggest an important role for
this chaperone to protect cortical neurons from stress
and toxic eﬀects administered during longer post incubations and viral infections. Detection of enhanced
HSP70 loads in neuronal exosomes may also suggest
a similar neuroprotective function. Our multiple
attempts with cryo-EM analysis revealed no detection
of virions/viral particles in any collected images. We
did not observe any virion(s) or viral particles neither
inside nor outside exosomes. We have used 72 h p.i.,
as the selected time point for exosome isolation and
cryo-imaging analysis. Usually for virus structure
determination, concentrated supernatants collected
from longer times of infection (7–14 days p.i.) with
high viral titres ranging from 109 to 1012 PFU/ml and
high centrifugal forces around 200,000 g are reported
[18,45,47]. These conditions were not used in our neuronal exosome preparations. In our analysis, exosomes
were found to exist in heterogenous populations varying from sizes of 30–200 nm. However, larger exosomes or EVs were also observed in a size range of
200–350 nm. ZIKV-infected neuronal cell-derived exosomes showed higher percentage of smaller exosomes
(0–200 nm in diameter) or larger EVs (200–500 nm
in diameter) suggesting dense packaging or greater
cargo transport through these exosomes, respectively.
Presence of HSP70, along with CD63 and CD9 in fractions 3–5 suggested these fractions to be exosomes
(perhaps containing exosomes 30–200 nm in size)
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due to the presence of enriched exosomal markers.
Enhanced detection of ZIKV-E-protein in fraction
four suggested that viral proteins are enriched in exosomes of sizes 100–200 nm that may correspond to
fractions three and four. The presence of high amount
of viral RNA and proteins in neuronal exosomes when
compared with neuronal cells, suggest dense packaging
of viral components in exosomes for transmission to
neighbouring neurons. Infection of naïve recipient cortical neuronal cells with infectious exosomal fraction
four containing enhanced viral E-protein showed the
presence of more viral RNA and its correspondence
to increased infectivity. Higher amounts of viral Eprotein in exosomal fraction four directly correlated
with increased transmission. Also, our data suggest
that ample amount of viral RNA and proteins inside
cells may randomly get transported into exosomes for
transmission to neighbouring neurons resulting in dissemination within the brains. The observation of no
diﬀerences in viral loads or infectivity via exosomes
treated with RNaseA or antibodies (ZV-2, ZV-16 or
ZV-54 or ZV-67), further suggests the presence of
viral RNA and proteins inside exosomes. An antibody
binding to the surface of the virus particles leads to
neutralization of viral infectivity. The 4G2 monoclonal
antibody has been shown as highly cross-reactive to
several of the ﬂaviviruses. However, a recent report
has described 4G2 antibody as a poor neutralizing antibody for ZIKV [59]. Our study showed that the neutralization eﬀects with 4G2 were lower when
compared with the other tested antibodies such as
ZV-2 or ZV-16. Furthermore, use of ZV-54 or ZV67, the highly potential neutralizing antibodies,
suggested ZV-2 or ZV-16 antibodies are less potential
in comparison to the ZV-54 and ZV-67 antibodies.
These ﬁndings are in agreement with the previous
study that tested neutralization eﬀects on diﬀerent
ZIKV strains [48]. However, similar results with no
diﬀerences in viral loads or infection were observed
with infectious exosomes upon use of any of these
antibodies (ZV-2, ZV-16, ZV-54 or ZV-67 or 4G2),
suggesting that viral E-protein is located inside the
lumen of these vesicles and not exposed on the surface
for binding to these neutralizing antibodies. Infections
of naïve recipient cortical neuronal cells via infectious
neuronal exosomes further suggest exosomes as novel
modes for ZIKV transmission. We assume that exosome-mediated spread is very fast and eﬃcient instead
of matured virions-receptor mediated transmission. In
exosomes, abundant amount of viral RNA and proteins can be transmitted and they can highly be infectious in recipient cells. Also, it is safe for the viral
RNA and proteins to be protected and transported
as cargo to recipient cells via secured exosomes that
can avoid any immune checkpoints during transfer
via longer routes such as periphery to the brain in vertebrate host.
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Neutral Sphingomyelinase 2 (SMPD3/nSMase), or
sphingomyelin phosphodiesterase is an enzyme that
is responsible for cleaving sphingomyelin (SM) to
phosphocholine and ceramide, a second messenger
involved in multiple cellular responses including stress
[38,39]. Our cryo-EM analysis indicated increased production and release of neuronal exosomes, upon ZIKV
infection. We assume that increased activation and
levels of SMPD3, in neuronal cells perhaps is associated
with the increased release of exosomes upon ZIKV
infection. Detection of SMPD3 mRNA levels showed
no signiﬁcant diﬀerences in neuronal exosomes, however, its higher enzymatic activity in both neuronal
cells and exosomes suggest that SMPD3 is critical for
the release of neuronal exosomes during ZIKV infection. We propose that similar to increased SMPD3
protein levels detected in neurons, exosomes perhaps
have higher protein loads. Silencing of smpd3 in cortical neurons showed a signiﬁcant reduction in viral
loads thereby, indicating a requirement for this neutral
sphingomyelinase in mediating ZIKV infection. These
data suggested that ZIKV-infection could enhance the
production and/or release of exosomes from cortical
neurons by increasing the protein and activity of
SMPD3. The cell density independent increase in
SMPD3 activity in exosomes in comparison to cells
(from which exosomes were derived) suggests a strong
role of this enzyme in production and release of exosomes. In cells, SMPD3 activity was mostly maintained
as the growing cells retained same fold of activity that
was independent of the cell numbers plated. In human
macrophage THP-1 cells, SMPD3 has been shown to
contribute to secretion of exosomes by triggering the
budding of exosomes into MVBs [60,61]. Inhibition
of SMPD3 either through shRNA or siRNA or
GW4869 inhibitor treatment has been shown to inhibit
the release of exosomes [49,54,61]. GW4869 is a
pharmacological agent that aﬀects neutral sphingomyelinase activity and blocks exosome production
and release [49]. Very recently it has been shown that
GW4869 can inhibit ZIKV infection by perhaps aﬀecting the neutral Spingomyelinase-2 in human foetal
astrocytes, however, no insights into the sphingomyelin metabolism was addressed [62]. GW4869 inhibitor
is been also shown to inhibit the ceramide-mediated
budding of MVBs and release of mature exosomes
from MVBs [41,49,60,61,63]. The reduction in viral
loads upon treatment with GW4869 (in a dose- and
time-dependent manner) suggests that GW4869 may
be considered as a candidate for the development of
novel therapeutic to control ZIKV infection and transmission in and between cortical neuronal cells. In both
cortical neurons and neuronal cell-derived exosomes,
decreased ZIKV loads correlated with reduced
SMPD3 activity and levels upon GW4869 treatment
in a dose- and time-dependent manner. This data
suggest that SMPD3 facilitates ZIKV infection and

transmission through neuronal exosomes in order to
disseminate the infectious viral RNA and proteins. It
will be highly interesting to understand the mechanism
of how SMPD3 facilitates ZIKV replication in neuronal
cells. Our immediate future avenues will focus on this
novel aspect to address the importance of SMPD3
and other neutral Sphingomyelinases in ZIKV infection and neuropathogenesis. The presence of higher
ZIKV loads in exosomes when compared with neuronal cells suggests that ZIKV infectious RNA and proteins are perhaps abundantly been packaged and
maintained to transmit through neuronal communication. We assume that higher amount of GW4869
inhibitor is essential in reducing the ZIKV loads in
neuronal cells. We also noted that longer incubations
and increased amounts of the inhibitor showed dramatic eﬀects in reducing ZIKV loads in neuronal exosomes. The presence of higher loads of ZIKV infectious
RNA and proteins in exosomes may lead to increased
transmission causing neuropathogenesis and ultimately death/loss of cortical neurons. Our immediate
future research eﬀorts will address the underlying molecular mechanisms of SMPD3 and other neutral Sphingomyelinases in mediating the transmission of ZIKV
and its detrimental eﬀects in causing microcephaly in
neonatal brains.
Given the importance of SMPD3 in mediating
transmission of ZIKV through neuronal exosomes
and GW4869 in inhibiting the viral loads in both neuronal cells and exosomes, we propose both as possible
therapeutic candidates for controlling ZIKV infection
and transmission in developing brains. Our longterm future avenues will also delineate the schemes
that depend on neutral Sphingomyelinases including
SMPD3, that lead to enhanced cortical neuronal
death, and the underlying molecular mechanisms for
ZIKV-caused microcephaly in developing/neonatal
brains. The decreased size in microcephalic brains of
ZIKV infected neonates is caused by a gradual decrease
in neuron production or due to the rapid loss of dendritic connections [2,8,15,16]. Higher secretion and
transport of infectious exosomes through axonal
transport may transmit ZIKV infectious RNA and proteins to the dendritic branches of the receiving neurons, thereby decreasing the dendritic branching or
arborization. Alternatively, if ZIKV uses exosomes
for transmission in the CNS, it could spread the infectious viral RNA and proteins to neural stem cells and
thereby manipulate the progenitor cells. Both these
scenarios would ultimately lead to decreased
neuronal numbers and act as a factor responsible for
ZIKV-caused neuronal cell death and microcephaly.
Delineating the importance of exosomes and exosomes-associated host molecules that mediate and
facilitate ZIKV transmission would unravel the molecular mechanism(s) of infection by this neurotropic
virus.
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Materials and methods
Isolation and culture of murine cortical neurons
and infection with ZIKV
C57BL/6 wild-type female mice with gestation period
(day13) were purchased from Charles River Laboratories and allowed to reacclimatize in our animal facility. Following ethical rules and regulations in
accordance with the institutional Animal Care and
Use committee, we performed all mice experiments.
All animal work in this study was carried out in strict
accordance with the recommendations in the Guide
for the Care and Use of Laboratory Animals of the
National Institute of Health. Institutional Animal
Care and Use Committee (Animal Welfare Assurance
Number: A3172-01) approved protocol was used in
this study (permit number: 16-017). Primary cultures
of murine cortical neurons as disassociated cells were
isolated from embryonic day- (E16) brains [18,64,65].
Murine cortical neuronal cells (2 × 105) were seeded
in a 12-well plate and cultures were established in complete neurobasal medium with 10% FBS. One day postplating (DIV; Day in vitro 1), half of the medium was
replaced with FBS-free media, to control the growth
of glial cells. After 48 h of plating, we observed initiation
of neuritogenesis, and cortical neurons were infected
with ZIKV (MOI 5 or with diﬀerent MOI 1, 2.5 or 5;
in dose–response experiments) at 72 h post plating.
Neurons were collected at either diﬀerent time points
(24, 48, 72, 96 or 120 h p.i., in infection kinetics and
inhibitor treatment assays) or at 72 h p.i., in case of
dose–response and other in vitro assays (as indicated
in respective Figures and Figure legends). Following
collection of neuronal cells and isolation of exosomes,
we processed samples for RNA extractions and RealTime Quantitative PCR (QRT-PCR). All culture medium and required supplements for neuronal culture
isolation and maintenance were purchased from Invitrogen/ThermoScientiﬁc Inc. ZIKV PRVABC59 strain
was obtained from BEI resources (catalog number:
NR-50240) and propagated as per the instructions
from the distributor. Due to increased viral loads in cortical neurons at 72 h p.i., we considered this time point
for further analysis. Details for infection studies corresponding to the data shown in diﬀerent ﬁgures is mentioned in the respective ﬁgure legends. Brieﬂy, for reinfection experiments with infectious exosome fractions, 2 × 105 neurons were co-incubated with 20 µl of
neuronal cell-derived exosomal fractions. We used
400 µl (same ratio) of exosome-depleted supernatant
fraction (collected from the step before PBS wash
during exosome isolation, see our recent published
study [18]) from neuronal cells processed for isolation
of exosomes. Neuronal cells were harvested at diﬀerent
time points (24, 48, 72 and 96 h p.i.) and processed for
RNA extractions followed by QRT-PCR.
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Immunoﬂuorescence, Phase contrast and
ﬂuorescent microscopy
2–5 × 105 neuronal cells were plated in complete neurobasal medium and allowed to adhere for overnight.
Two days post-plating (DIV 2) neuritogenesis was
observed, cortical neurons were infected with ZIKV
(MOI 5; in time point samples or with diﬀerent
MOI’s 1, 2.5, 5 in dose–response experiment) at either
72 or 120 h post plating. Immunoﬂuorescence (IFA)
was performed as described [47]. Brieﬂy, cortical neuronal cells were ﬁxed with 4% PFA, permeabilized,
blocked (3% BSA) and stained with MAP-2 antibody
(Santa Cruz Biotechnology, Inc.) followed by detection
with Alexa-Fluor 488 secondary antibody. Sequentially
neurons were further stained for either GFAP antibody
(Santa Cruz Biotechnology, Inc.) or 4G2 monoclonal
antibody (that detects ZIKV E-protein) followed by
detection with Alexa-Fluor 594 secondary antibody,
respectively. Neuronal cell nuclei were detected with
DAPI staining. Fluorescent images were obtained
from 72 or 120 h p.i. cortical neuronal cells. Phase contrast images were collected from both uninfected and
ZIKV-infected cells at diﬀerent days or time points
(24, 48, 72 and 96 h p.i.) or at 72 h p.i. in neurons
infected with diﬀerent MOI (infection with dose–
response or virus dilution assays). For neutralization
assays with ZV-2, ZV-16 or ZV-54, ZV-67 antibodies
[48], neurons were ﬁxed and processed as described
above, and immunostained with 4G2 monoclonal antibody, followed by detection with Alexa Fluor 594 secondary antibody. Untreated cells represent no
antibody treatments but were incubated either with
infectious exosomes or with viral stocks (of known
titres as described above). All cells were treated with
DAPI to show cell nuclei in addition to bright ﬁeld
images that served as controls. Images were obtained
using the EVOS Fluorescence System (Invitrogen/
ThermoScientiﬁc Inc.) and 10X or 20X (in Figures 1,
5) or at 10X magniﬁcation (in Supplementary Fig. 1).
Representative images are shown for each time point
or group. Scale bar is shown on each representative
image in the respective groups.

MTT assays
MTT [3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl-2Htetrazolium bromide] assay was used to measure viability, which served as an index of living neuronal cells.
Brieﬂy, 5 mg/ml of stock solution was prepared by
completely dissolving MTT (Sigma) in DMSO
(100%) and followed by ﬁlter sterilizing (0.22 µm
ﬁlter; Nalgene). Primary cultures of cortical neuronal
cells were plated at the density of 1 × 104 cells per
well in a 96-well plate. The conﬂuence of the cells
was less than 100% in all wells. For infection, we
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infected neuronal cells with ZIKV (MOI = 5) and at
diﬀerent time points (24, 48, 72, 96 and 120 h) post
infection, then we removed all medium from each
well, and added 90 µl of fresh medium to each well.
100 µl of PBS was added to empty wells for background
estimation. 10 µl of prepared MTT solution was added
to all the wells including PBS containing wells that
served as blank controls. Plates were covered in aluminium foils and incubated at 37 °C for 2–4 hrs
(until purple precipitate was visible). 100 µl of DMSO
solvent was added and plates were incubated at 37°C
for another 15 min. Absorbance was read at 560 nm
and for reference plates were read at 650 nm. The uninfected control maintained for 120 h post plating was
considered to calculate the percentages of cell viability.
Values from 650 nm reference read were subtracted
from the values obtained at 560 nm to determine the
neuronal cell viability numbers. Higher absorbance
values indicated an increase in cell viability.
RNA extraction, cDNA synthesis, and QRT-PCR
analysis
Following manufacturer’s instructions, total RNA was
extracted using Aurum Total RNA Mini kit (BioRad).
RNA was extracted from cortical neurons or neuronal
cell-derived exosomes infected (5 MOI) at indicated
time points (24, 48, 72, 96 h p.i.) or with various
doses (MOI 1, 2.5, 5) of ZIKV-infected group or uninfected controls. RNA was converted to cDNA using the
BioRad iScript cDNA synthesis kit. The generated
cDNA was used as template for the ampliﬁcation and
determination of viral burden. For detection of ZIKV
replication, published forward and reverse primers
for NS5 or E-gene region were used [66,67]. For
SMPD3 gene expression analysis we used the following
forward and reverse primers from published study
[68]. To normalize the amount of templates, mouse
actin amplicons were quantiﬁed with published primers [18]. Primers for beta-actin were used in parallel
for QRT-PCR normalization. GAPDH primer
sequences were designed based on the published
study [69]. Equal amounts of mouse cDNA samples
were used in parallel for beta actin, gapdh and ZIKV
E-gene or NS5 gene. The ratio of ZIKV E-gene or NS5
amount/beta actin amount was used as an index to
determine the rate of infection in each analysed sample.
QRT-PCR was performed using iQ-SYBR Green
Supermix and CFX96 instrument (BioRad, USA). Standard curves were prepared using 10-fold serial
dilutions starting from standard 1–6 of known quantities of actin or gapdh or ZIKV E-gene or NS5 gene
fragments and QRT-PCR reactions were performed
as described [18]. For RNaseA treatment, we isolated
fresh exosomes from either uninfected or ZIKVinfected neuronal cells (2 × 107), distributed the
infected exosomes as treated (5 µg/ml RNase, 37°C

for 15 min) or untreated groups. Uninfected exosomes
(as similar volumes used in infected groups) treated
with RNaseA were used as control. For ZIKV laboratory viral stocks (5 MOI), we treated the viral supernatants directly with RNaseA and incubated these
samples on naïve primary cultures of murine cortical
neurons. Non/poorly neutralizing antibodies ZV-2,
ZV-16, or 4G2 (Clone D1-4G2-4-15) were obtained
from BEI resources. The highly potent neutralizing
antibodies ZV-54 and ZV-67 [48] were a kind gift
from Dr. Michael S. Diamond’s laboratory, at the
Washington University School of Medicine, Saint
Louis, MO. For ZV-2, ZV-16 or ZV-54, ZV-67 or
4G2 antibodies treatments or neutralization studies,
we treated either 3 µg (of ZV-2, ZV-16 or ZV-54,
ZV-67) or 5 µg (of 4G2 antibody) of antibodies for
4 h at 37°C with either freshly isolated exosomes
(20 µl of PBS suspension of exosomes from ZIKVinfected cells, 72 h p.i., 5 MOI) or with ZIKV laboratory viral stocks (8 MOI as high dose or 0.8 MOI as
low dose for ZV-2, ZV-16 or ZV-54, ZV-67 antibodies
or 5 MOI for 4G2 antibody treatments). In order to
adjust the dose and reﬂect the infection of recipient
cells with infectious exosomes, we have used either
high or low doses of viral stocks with known titres
for comparison. Exosomes were collected from independent batch of ZIKV-infected or uninfected cells
and were used in this analysis. Neuronal cells were
infected through infectious exosomes or viral stocks
(pretreated with respective antibodies) for 72 h p.i.,
and collected for RNA extractions and processed for
QRT-PCR. Untreated samples or neurons incubated
with exosomes from uninfected cells served as experimental internal controls.
Immunoblotting and densitometry analysis
Brieﬂy, 2 × 107 cortical neuronal cells were seeded on to
six well-dishes for overnight incubation. Next day, we
changed half of the complete media to no-FBS containing medium. Cells were infected with ZIKV (MOI 5) at
72 h post plating, and collected at diﬀerent time points
of 24, 48, 72, and 96 h p.i. or with diﬀerent doses, of 1,
2.5 and 5 MOI. Cell culture supernatants were collected
from the same cells at diﬀerent time points (24, 48, 72,
and 96 h p.i.) of infection or at 72 h p.i. (from diﬀerent
MOI samples) and processed for exosome isolation.
Exosome fractions were collected after PBS wash
(two times), and adherent cells were collected from
the same plates (washed twice with 1 × PBS), and
resuspended in modiﬁed RIPA buﬀer. Total protein
amounts were estimated using BCA kit (Pierce/ThermoScientiﬁc, Inc.). Whole cell and exosomal lysates
(10–30 µg) were separated on 12% SDS-PAGE gels.
After gel electrophoresis, blots were blocked with 5%
milk buﬀer and probed with either 4G2 (obtained
from Millipore, Sigma or BEI resources) or HSP70
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(Cell Signaling Technologies, Inc) or CD63 or CD9
monoclonal antibodies or SMPD3 polyclonal antibody
(Santa Cruz Biotechnologies, Inc), followed by mouse
or rabbit HRP-conjugated secondary antibodies
(Santa Cruz Biotechnologies, Inc), respectively. Images
showing total protein proﬁles obtained from Coomassie-stained gels served as loading controls. Antibody
binding was detected with WesternBright ECL kit
(Advansta, BioExpress). Blots were imaged using Chemidoc MP imaging system and processed using Image
Lab software obtained from the manufacturer
(BioRad). Densitometry analysis from total cell and
exosomal lysates (from both the time point and
dose–response immunoblot analysis) between the
ZIKV infected (MOI 5) and uninfected controls was
performed considering their respective total proﬁle
gel images and the respective band.
Isolation of exosomes from cell culture
supernatants
Exosomes were isolated by diﬀerential ultracentrifugation method [46]. Isolation procedure and modiﬁcations are shown in our recent study [18]. Brieﬂy,
1–2 × 107 cortical neuronal cells were seeded for exosome isolation in complete neurobasal medium (overnight). Neurons were infected with ZIKV (MOI 5) for
72 h p.i.. Brieﬂy, cell culture supernatants were spun at
100,000 × g for 120 min. Supernatants collected after
this spin served as exosome-depleted supernatant
(EDS) fractions (used as control in our study). The pellet containing exosomes and any contaminants were
washed with ice-cold PBS (another spin at 100,000 ×
g, for another 120 min). Resulting exosome pellet is
referred as exosome fractions in our study. Freshly prepared exosome pellets were resuspended in PBS and
either frozen at −80°C or used for subsequent evaluations and assays or were resuspended in RNA lysis
(Biorad) or modiﬁed RIPA buﬀers (G-Biosciences,
BioExpress) for total RNA or protein extractions.
Cryo-Electron microscopy
We performed the cryo-EM as published in our recent
study [18,47]. Brieﬂy, puriﬁed concentrated suspensions of ZIKV-infected or uninfected exosomes resuspended in PBS were vitriﬁed on carbon holey ﬁlm
grids and as previously described [70,71]. Frozen
grids were stored under liquid Nitrogen and transferred to a cryo-specimen holder under liquid Nitrogen
before loading into a JEOL 2200FS, or a JEOL 2100
electron microscopes (JEOL Ltd., 3-1-2 Musashino,
Akishima, Tokyo 196-8558, Japan). Preliminary
screening and imaging of exosomes was done using a
4k × 4k Gatan US4000 CCD camera and ﬁnal imaging
was done at indicated 40,000× magniﬁcation with a
5k × 4k Direct Electron Detector Camera using a low-
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dose imaging procedure. Images were acquired with a
ca. 20 electrons/Å2 dose; the pixel size corresponded
to 1.5 Å on the specimen scale. We used a 2.0–
2.3 µm defocus range for imaging. For exosome size
quantitations, we manually analysed the sizes using
scale bar from cryo-EM images and counted exosomes
of diﬀerent sizes per image in each group. Three independent estimations and countings were performed
without any bias. Percentages (for size determination)
were calculated based on the total number of exosomes
in each size range.
OptiPrep™ density gradient exosome (DG-Exo)
isolation
2 × 107 cortical neuronal cells were infected with ZIKV
(5 MOI and for 72 h p.i.). Uninfected neurons were
used as controls. The detailed protocol for isolation
of exosomes on density gradient is shown in our recent
published study [18,47]. Brieﬂy, supernatants (10 ml)
from uninfected/infected cortical neurons were collected and centrifuged at 4°C (480 × g followed by
2000 × g for 10 min each to remove cell debris and
dead cells). Cell culture supernatants were concentrated to ∼2 ml using the Corning Spin-X UF concentrators or centrifugal ﬁlter device with a 5 k nominal
molecular weight limit (NMWL) (VWR). Concentrated cultures were processed for OptiPrep™ (DGExos) isolation as described [18,45]. Six individual fractions were collected from uninfected or infected groups
(from top to bottom) manually after 18 h spin at
100,000 × g (with increasing density of iodixanol, and
smaller size vesicles on bottom fractions) and diluted
with 5 ml of sterile PBS. Fractions were centrifuged at
100,000 × g for 3 h at 4°C, followed by another PBS
wash and spin at similar centrifugal forces. DG-Exo
fractions were resuspended in 80 µl of PBS and stored
at −80°C until further analysis. Exosomal fractions
were either processed for Western blotting analysis to
detect viral E-protein or the exosomal marker HSP70
or used in infection of naïve primary cultures of murine
cortical neurons to determine the infectivity and transmission through infectious exosomal fractions.
Viral dilution assay
We performed the virus dilution assay as described in
[72]. Brieﬂy, neuronal cells were seeded (at a density
of 1 × 105 cells/well in 225 µl of Neurobasal complete
medium) on 96 well plates. Neurons were treated
with either exosome fraction (20 µl) or with exosome-depleted supernatant fractions (EDS; 400 µl) or
with laboratory ZIKV viral stocks (5 MOI) at 72 h
post plating and incubated for additional 5 days. In
each group, we had six diﬀerent dilutions (1–6) and
at least eight independent replicates in addition to
the uninfected negative controls. Neurons were ﬁxed
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with acetone-PBS mixture (3:1, for 20 min at −20°C)
and plates were air dried, washed with 1 × PBS and
blocked with 5% FBS-PBS-0.05% Sodium Azide for
15 min at RT. ZIKV E-protein was detected by incubation with 4G2 monoclonal antibody (overnight at
4°C), followed by three washes with PBS. Samples
were incubated with Alexa-594 labelled mouse secondary antibody for 1 h at RT, followed by washes (3×)
with PBS. Plates were analysed using EVOS ﬂuorescence system (Invitrogen/Thermoscientiﬁc, Inc.)
and cells were scored for ﬂuorescence or the presence
or absence of infection in comparison to the infected
positive controls (infected with laboratory prepared
virus stocks) or uninfected negative controls. Representative images from dilutions 106 are shown. Percentage
of infected neurons is shown from the same dilution for
exosome and supernatant fractions.
Neutral Sphingomyelinase activity assay
For determining the activity of neutral Sphingomyelinases, we used the Colorimetric Sphingomyelinase
Assay kit from SIGMA-Aldrich and followed the
instructions from the manufacturer. Brieﬂy, we plated
1 × 107 cortical neuronal cells and three-day post-plating infected with ZIKV (MOI 5) for either 24 or 72 h
p.i.. In an independent assay to test if increase in
SMPD3 activity is dependent/independent on cell
number and exosome production and/release, we plated mouse cortical neuronal cells at densities of 103,
104, 105, 106 and 107 cells per well in replicates and
measured the total protein amounts and SMPD3
activity. We measured SMPD3 activity by either considering the same amounts of total protein (estimated
by BCA assays), where SMPD3 activity was calculated
over the total protein amounts as shown in Figure 6
(C,D). We also considered equal volume of samples
for determining the SMPD3 activity (as shown in Supplementary Figs. 9A and 9D). The total concentration
of proteins estimated from uninfected or ZIKVinfected neurons or exosomes derived from these
neurons is shown in Supplementary Figs. 9B and
9C; for cells or 9E and 9F; for exosomes. At diﬀerent
time points post infection, cell culture supernatants
were collected and processed for exosome isolation.
Both cell and exosomal lysates were resuspended in
1 × PBS and were frozen at −80°C. We used 50 µl
for each time point sample (uninfected or ZIKVinfected) as 6 replicates. Absorbance from assay
samples was measured at 655 nm. Calculations were
performed using the Zero blank sphingomyelinase
standard that is considered as background blank. All
readings were substracted from the background
values. Standard curves were plotted using the standard values and the amount of active sphingomyelinase present in the samples was determined based
on the standard curve.

siRNA transfections and inhibitor studies
For siRNA transfections and silencing of smpd3, we
plated 1 × 106 of cortical neurons in complete neurobasal medium, allowed to adhere overnight, and changed
to half of medium without FBS on next day. For silencing of smpd3, speciﬁc siRNA (from Santa Cruz Biotechnologies, Inc.) were purchased and transfections
were performed as per the manufacturer instructions
and protocols. Cells were infected with ZIKV (MOI
5, at 72 h post plating) and collected at 72 h p.i. followed by RNA extractions and cDNA synthesis. Silencing eﬃciency of smpd3 was analysed by QRT-PCR.
For inhibition of exosome release from neuronal
cells, we used the selective inhibitor (GW4869) for
Neutral Sphingomyelinase 2 (nSMase2 or SMPD3)
(Santa Cruz Biotechnologies, Inc.) dissolved in
DMSO. Cytotoxicity of the inhibitor was ﬁrst analysed,
neurons did not show any toxicity at tested doses (of 1–
20 µM). For inhibitor studies, neurons (2 × 105 for
RNA and 1 × 107 for protein extractions) were plated
in complete neurobasal medium. Cortical neurons
were treated with GW4869 inhibitor (5, 10 or 20 µM)
for 4 h at 72 h post plating, followed by ZIKV infection
(5 MOI) at indicated time points (24, 48 and 72 h p.i.,
for both RNA and protein extractions). Cells treated
with similar volume (we considered volume used for
20-µM GW4869) of DMSO were considered as control
groups. Viral loads were determined at all tested time
points followed by QRT-PCR analysis. Both whole
cells and exosomal lysates (30 µg) were processed for
immunoblotting with 4G2 monoclonal antibody, followed by secondary antibody to detect ZIKV E-protein.
Statistics
Using GraphPad Prism6 software and Microsoft Excel,
we analysed the statistical signiﬁcance of diﬀerence
observed in data sets. Non-paired, two-tail Student ttest was used (for data to compare two means) for
the entire analysis. Error bars represent mean (+SD)
values, P values of <0.05 were considered signiﬁcant
in all analysis. Statistical test and P values are indicated
for signiﬁcance in all ﬁgures.
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